PALADIN Consortium’s Post

The Advocate: Supporting the Patient Voice's 2024 US Focused Patient Advocacy Report sheds light on the pharmaceutical industry's efforts to prioritize patient needs and collaborate with advocacy organizations. The report reveals that Johnson & Johnson ranks first for advocacy, commended for its 'willingness to collaborate with patient advocacy organizations beyond funding' and 'taking a holistic approach to building relationships.' Amgen showed significant improvement, praised for being 'highly innovative and forward-thinking' in engaging with patient groups. Pfizer remained consistent, recognized for 'obtaining patient perspectives for advancing care and in helping access to care.' Sanofi garnered appreciation for 'fostering education of health equity by forming communities of practice groups among patient organizations.' Other notable performers include AstraZeneca for policy support, Eli Lilly and Company for neurology groups, Merck for non-disease-specific groups, and Bristol Myers Squibb for immunology groups. 'The Advocate: Supporting the Patient Voice's goal is to understand the relationship between advocates and the pharmaceutical industry, ensuring that patients remain at the center of all healthcare decisions,' the report states. #patientadvocacy #patientcentric #pharmaceuticalindustry The Brooks Group, Inc.

In our latest video, we explore the partnership between pharmaceutical companies and patient advocacy groups. Discover how this collaboration amplifies patient voices and accelerates medical research. Click the link to check out our video! #PatientAdvocacy https://bit.ly/41RwEZf

The power of collaboration in healthcare cannot be overstated! Check out our article exploring the partnership between pharmaceutical companies and patient advocacy groups. This enhances patient outcomes and elevates the healthcare experience. #Pharma https://bit.ly/3tmPvP5

How Japan and India Can Revolutionize Pharma Together? It was an Incredible and insightful convo with DR. Gurpreet Sandhu, Founder of Reva Pharmaceuticals, President of the Council of Healthcare & Pharma (CHP), A global think-tank advocacy forum watch the full video on my youtube channel : https://lnkd.in/ggkS5UQp #revapharma #pharma #pharamaceuticals #Inspiration #Yogannanupur #NupurTewari #ConnectIndiaJapan #TrendingReels #explorepage

🔎 The majority of rare diseases do not have specialized treatment.   Developing treatments for rare diseases poses unique challenges: ↳ including small patient populations for clinical trials ↳ limited understanding of disease mechanisms ↳ high research and development costs   The journey from research to market approval is long and complex.   Collaborations between pharmaceutical companies, research institutions, and patient advocacy groups can accelerate the development of new therapies.   Every effort counts in the fight against these overlooked conditions.   And everyone deserves access to care, no matter how rare their condition.   👣 Follow us and take your PV to the #NextLevel! 🚀   #NextPVUniversity   #HealthcareInnovation #OrphanMedicines #Orphan #RareDisease #OrphanDrugs #RareDiseases #Pharmacovigilance #PatientCare

We are just one week away from Rare Disease Day! Be on the lookout next week for our special podcast episode during which Angela Wheeler, President of Insight US at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD) discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Discussion highlights include the importance of: - continued support for the development of rare disease treatments - making a push towards more equitable clinical trial populations - focusing on how we can reduce the barriers to access - bringing in the patient perspective and patient voice in every step of the drug development process #rarediseaseday #rarediseases #raredisorders #patientvoice #patientadvocacy #rarediseaseday2024

We are just one week away from Rare Disease Day! Be on the lookout next week for our special podcast episode during which Angela Wheeler, President of Insight US at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD) discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Discussion highlights include the importance of: - continued support for the development of rare disease treatments - making a push towards more equitable clinical trial populations - focusing on how we can reduce the barriers to access - bringing in the patient perspective and patient voice in every step of the drug development process #rarediseaseday #rarediseases #raredisorders #patientvoice #patientadvocacy #rarediseaseday2024

The end is fast approaching! Just 1 day to go until registrations close for the Patient Partnership Index 2023.    If you would like to showcase your involvement in a partnership between biopharmaceutical companies and patient organisations across communications, advocacy, market access, clinical trials, or R&D, register now to submit an entry.     Entries can be led by either partner and will be judged against a bespoke metric developed in partnership with industry and patient organisations to award Gold, Silver or Finalist standards.    Entries to the Index close at 23:55 on Friday 26th April, so register now to receive an entry form, and ensure your partnerships get the recognition they deserve.     The registration form, alongside FAQs and insights from last year’s Index, can be found via the link in comments.    If you have any questions or require further support to get your entry (or entries) in by Friday, please reach out to the PPI team at [email protected].     #clinicaltrials #marketaccess #researchanddevelopment #patientadvocacy #healthcarecommunications 

Mega proud to be part of this wonderful initiative. If you are involved in a partnership between biopharmaceutical companies and patient organisations, there is still time to register to take part via the link below!! Partnerships can be in any of the following: 💗Communications 📢 Advocacy 🌐Market Access 🔬Clinical trials 🧪R&D #patientadvocacy #marketaccess #healthcarecommunications

We are thrilled to announce the continued collaboration between Astellas and Patient Advocacy Leaders and Drug Development Industry Network (PALADIN), as well as the launch of the highly anticipated PALADIN Playbook and Resource Repository. This collaboration represents an important milestone in our efforts to advance patient advocacy group (PAG) and industry collaborations, with the ultimate goal of increasing access to life-saving treatments. PALADIN Consortium, in which Astellas is an active participant, plays a pivotal role in establishing more effective relationships between PAGs and biopharmaceutical companies. By developing consensus-based guidelines, training, resources, and competencies, PALADIN aims to optimize collaborations and transform the pace of new medical therapies' development. We are excited about the potential of this collaboration and the impact it will have on relevant stakeholders and the community. Together, we can create meaningful change and drive progress in the industry. Stay tuned for further updates and announcements as we continue this exciting journey with PALADIN. For more information, including PALADIN Playbook and Resource Repository, visit https://lnkd.in/gPk4H8M7. #PatientAdvocacy